These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 20088792)

  • 1. Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting.
    Santini D; Virzi V; Fratto ME; Bertoldo F; Sabbatini R; Berardi R; Calipari N; Ottaviani D; Ibrahim T
    Curr Cancer Drug Targets; 2010 Feb; 10(1):46-54. PubMed ID: 20088792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature.
    Gnant M; Clézardin P
    Cancer Treat Rev; 2012 Aug; 38(5):407-15. PubMed ID: 21983264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous bisphosphonates for breast cancer: impact on patient outcomes and scientific concepts.
    Gnant M
    Breast Dis; 2011; 33(2):71-81. PubMed ID: 22142663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role of bisphosphonates of adjuvant therapy in breast cancer].
    Gálvez-Muñoz E; Rodríguez-Lescure Á
    Med Clin (Barc); 2010 Jun; 135(2):70-4. PubMed ID: 20022069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronic acid in the management of metastatic bone disease.
    Santini D; Fratto ME; Vincenzi B; Galluzzo S; Tonini G
    Expert Opin Biol Ther; 2006 Dec; 6(12):1333-48. PubMed ID: 17223741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New developments of aminobisphosphonates: the double face of Janus.
    Santini D; Galluzzo S; Vincenzi B; Schiavon G; Fratto E; Pantano F; Tonini G
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi164-7. PubMed ID: 17591815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of zoledronic acid in the treatment of breast cancer].
    Chen J; Liu ZY; Zhao LJ
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):318-9. PubMed ID: 21575510
    [No Abstract]   [Full Text] [Related]  

  • 8. Anticancer activity of bisphosphonates in breast cancer.
    Gnant M
    Anticancer Agents Med Chem; 2012 Feb; 12(2):114-22. PubMed ID: 21864231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases.
    Niikura N; Liu J; Hayashi N; Palla SL; Tokuda Y; Hortobagyi GN; Ueno NT; Theriault RL
    Cancer; 2012 Apr; 118(8):2039-47. PubMed ID: 22139648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging strategies in bone health management for the adjuvant patient.
    Coleman RE
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S11-6. PubMed ID: 18068485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should bisphosphonates be utilized in the adjuvant setting for breast cancer?
    Lipton A
    Breast Cancer Res Treat; 2010 Aug; 122(3):627-36. PubMed ID: 20490653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronic acid: past, present and future roles in cancer treatment.
    Saad F
    Future Oncol; 2005 Apr; 1(2):149-59. PubMed ID: 16555985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?
    Steinman RA; Brufsky AM; Oesterreich S
    Breast Cancer Res; 2012 Sep; 14(5):213. PubMed ID: 23014660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid in the treatment of metastatic breast cancer.
    Lluch A; Cueva J; Ruiz-Borrego M; Ponce J; Pérez-Fidalgo JA
    Anticancer Drugs; 2014 Jan; 25(1):1-7. PubMed ID: 24100278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
    James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
    Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates and breast cancer incidence and recurrence.
    Chlebowski RT; Col N
    Breast Dis; 2011; 33(2):93-101. PubMed ID: 22142660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates and breast cancer prevention.
    Chlebowski RT; Col N
    Anticancer Agents Med Chem; 2012 Feb; 12(2):144-50. PubMed ID: 21864227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
    Smidt-Hansen T; Folkmar TB; Fode K; Agerbaek M; Donskov F
    J Oral Maxillofac Surg; 2013 Sep; 71(9):1532-40. PubMed ID: 23642545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates in breast cancer: antitumor effects.
    Aft R
    Clin Adv Hematol Oncol; 2011 Apr; 9(4):292-9. PubMed ID: 21558988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.